STRUCTURAL HEART THERAPIES
We are passionate about providing advanced transcatheter therapies that help you improve patient outcomes and improve the quality of patient lives.EXPLORE NOW
You are now going to a third-party website. We don’t review or control and are not responsible for the content on non-Boston Scientific websites.
We share your passion to:
Improve outcomes and patient quality of life
Advance transcatheter structural heart therapies
Drive development of innovative technologies
Boston Scientific makes a strategic investment in Millipede, Inc. IRIS Annuloplasty Ring System Transcatheter-based treatment for severe mitral regurgitation.
Boston Scientific makes a
strategic investment in Millipede, Inc.
IRIS Annuloplasty Ring System
Transcatheter-based treatment for
severe mitral regurgitation.
LEARN MORE ›
WATCHMAN™ LAAC Device:
Five Year Results from PROTECT AF and PREVAIL
Published in JACC Demonstrated WATCHMAN
Reduced Risk of Stroke, Bleeding and Mortality*
*Comparable primary efficacy and all-cause stroke reduction, statistically significant reductions in disabling and fatal stroke (largely driven by reduction in hemorrhagic stroke), major non-procedure related bleeding as well as mortality, at 5 years vs. long-term warfarin therapy.
LEARN MORE ›
ACURATE neo™ Aortic Valve System:
Safey and efficacy results comparable
to SAPIEN 3 in MORENA,
a multicenter-comparison Study.1
1Husser O, et al. Multicenter comparison of novel self-expanding versus balloon-expandable transcatheter heart valves. JACC Cardiovasc Interv. 2017 Oct 23;10(20):2078-2087.
LOTUS™ Aortic Valve Platform: superior efficacy
to Evolut™ R / CoreValve™ in
Global REPRISE III Trial at One Year1*
1Presented by T. Feldman, MD at EuroPCR2017
* Primary effectiveness endpoint (1 year): Composite of all-cause mortality, disabling stroke, moderate or greater PVL. LOTUS Valve = 15.8% vs. Evolut R / CoreValve Platform = 26.0%. Superiority P < 0.001. Primary safety endpoint (30 days): Composite of all-cause mortality, stroke, life-threatening and major bleeding events, stage 2/3 kidney injury, major vascular complications. LOTUS Valve = 20.3% vs. Evolut R / CoreValve Platform = 17.2%. Non-inferiority P = 0.003.
CAUTION: Investigational Device. Limited by US law to investigational use only. Not available for sale. LEARN MORE ›